ES502 / Shanghai Essight Biotechnology - LARVOL DELTA

A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Ruijin Hospital

New P1 trial • Cholangiocarcinoma • Colorectal Cancer • Endometrial Cancer • Gallbladder Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • HLA-DPB1 • HRAS • KRAS • NRAS

Shanghai Essight Biotechnology Co., Ltd. announced that ES502 Injection has received FDA approval to proceed with a Phase I clinical trial for patients with advanced solid tumors harboring RAS G12V mutations (KRAS/NRAS/HRAS) (flcube.com) - "ES502 becomes the world’s first TCR×CD3 bispecific T‑cell engager (TCE) targeting the RAS G12V neoantigen to enter clinical development, with potential to address 30–70% of global patients carrying this prevalent oncogenic driver mutation."

IND • New P1 trial • Solid Tumor